GH-releasing tesamorelin has rapidly shaken up the landscape for metabolic research, opening new doors for understanding how to control visceral fat, stimulate lipolysis, and revolutionize body composition management. As a potent synthetic growth hormone-releasing hormone (GHRH) analog, tesamorelin has captured the attention of scientists and clinicians alike, thanks to its targeted effects on metabolism, visceral-fat reduction, and IGF-1 secretion.
Important: Tesamorelin and all peptides discussed in this article are strictly for laboratory research purposes only and are not intended for human consumption, therapeutic use, or animal treatment.
Tesamorelin represents a strategically designed peptide structure that enhances endogenous secretion of growth hormone (GH), setting off a remarkable cascade that influences not only body composition but also cardiovascular health markers. At Oath Research (OathPeptides.com), we are at the forefront of providing research-quality tesamorelin for investigative purposes. Let’s take an in-depth look at the science and promise behind this outstanding GH-releasing compound.
GH-Releasing Tesamorelin: How It Targets Visceral Fat and Drives Lipolysis
The focus on GH-releasing peptides like tesamorelin is due largely to their unique ability to modulate the body’s endocrine system without the side effects associated with exogenous growth hormone administration. Tesamorelin acts as a selective GHRH analog, stimulating the pituitary to release GH in pulsatile bursts—closely mimicking natural secretion patterns. This matters because accurate GH pulsatility is crucial for optimal metabolic signaling, particularly with respect to lipolysis and visceral fat decomposition.
Research reveals that tesamorelin’s most dramatic effect lies in its capacity to reduce visceral fat—the deep, metabolically active fat surrounding internal organs. In a landmark randomized trial published in the New England Journal of Medicine, tesamorelin decreased visceral adipose tissue by 15.2% compared to a 5.0% increase in the placebo group over 26 weeks, while also significantly reducing triglyceride levels [1]. Unlike subcutaneous fat, visceral adiposity increases inflammation, disrupts insulin sensitivity, and raises cardiovascular risk. Tesamorelin’s action triggers a surge in GH, which in turn elevates IGF-1 levels. The downstream signaling through IGF-1 lends further support to fat breakdown (lipolysis), muscle preservation, and an overall improvement in body composition.
A pivotal aspect here is tesamorelin’s selectivity: while it potently reduces visceral fat, it generally spares subcutaneous fat and does not lead to significant muscle wasting, making it a valuable tool for research into metabolic syndrome, HIV-associated lipodystrophy, and general obesity. A 2026 meta-analysis of five randomized controlled trials confirmed that tesamorelin produces significant reductions in visceral adipose tissue and trunk fat while increasing lean body mass, without significantly affecting subcutaneous fat or BMI [2].
Mechanisms: Tesamorelin, IGF-1, and Metabolism Optimization
How exactly does GH-releasing tesamorelin support a better metabolism? The peptide’s primary mechanism is by binding to and activating GHRH receptors on the pituitary gland, rapidly elevating GH release. GH, in turn, acts on multiple tissues:
– Adipose Tissue: Stimulates direct lipolysis by activating hormone-sensitive lipase, which breaks down stored triglycerides into free fatty acids. A study by Stanley et al. demonstrated that once-daily tesamorelin augments both basal and pulsatile GH secretion while preserving peripheral insulin-stimulated glucose uptake [3].
– Liver: Boosts IGF-1 synthesis, a critical growth factor that further amplifies fat breakdown and promotes muscle protein synthesis.
– Muscle: Drives anabolic processes, increasing lean mass while metabolizing adipose deposits.
This multi-targeted cascade is why tesamorelin and similar GH-releasing compounds have become cornerstones for metabolic and obesity research. Recent clinical data also points toward improved glucose metabolism, reduced inflammatory markers, and increased mitochondrial efficiency in energy utilization. Notably, transcriptomic analysis of liver biopsies from tesamorelin-treated subjects revealed increased expression of genes involved in oxidative phosphorylation and decreased expression of inflammatory pathway genes [4].
All tesamorelin research referenced herein is conducted under controlled laboratory conditions. These peptides are sold for research purposes only and are not for human or animal use.
Interested researchers can compare the effects of GH-releasing tesamorelin with our premium CJC-1295/Ipamorelin blend, another potent GHRH/GHRP synergistic peptide available at OathPeptides.com.
Body Composition: Real-World Improvements from GH-Releasing Peptides
Body composition—the ratio of fat to lean mass—matters immensely for overall health, longevity, and athletic performance. Studies consistently show that tesamorelin significantly decreases both total and visceral fat, improves waist circumference, and stabilizes lean muscle tissue. A randomized clinical trial published in JAMA found that tesamorelin reduced visceral adipose tissue by approximately 42 cm² and hepatic lipid content by 2.9% over six months compared to placebo [5].
What sets tesamorelin apart is its ability to lower deep abdominal fat (visceral fat), the most dangerous form associated with metabolic syndrome, diabetes, and cardiovascular risk. By ramping up endogenous GH and raising IGF-1, tesamorelin increases lipolysis without the water retention, insulin resistance, or desensitization sometimes seen with exogenous hGH.
For researchers seeking broader insights into body composition optimization, the hGH Fragment 176-191 also offers unique fat-burning properties and is available for research at OathPeptides.com.
Beyond Visceral Fat: Effects on Cardiometabolic Health
The influence of GH-releasing tesamorelin extends well beyond fat tissue. By consistently reducing visceral fat, tesamorelin research shows:
– Decreased triglyceride and cholesterol levels
– Lowered C-reactive protein (CRP), a key inflammation biomarker
– Improved liver fat content (hepatic steatosis) and liver function
These secondary benefits underscore the profound impact of visceral adiposity on chronic disease risk. Researchers are finding that addressing visceral fat with tesamorelin may confer ripple effects on the entire metabolic network, possibly improving insulin sensitivity and cardiovascular health over time. Notably, a 2024 study demonstrated that tesamorelin remains effective in reducing visceral and hepatic fat even in patients on integrase inhibitor-based antiretroviral regimens, which are themselves associated with weight gain [6].
“Lipolysis” is the technical term for fat breakdown – a process critical for researchers exploring obesity, fatty liver disease, and aging-related weight gain. Tesamorelin’s distinct advantage lies in targeted, visceral fat-specific lipolysis, not simply a broad reduction in all types of adipose tissue.
By leveraging the natural pulsatility of endogenous growth hormone, GH-releasing tesamorelin avoids excessive systemic effects, focusing its fat-reducing power on those stubborn internal stores that most impact health.
For investigators interested in tissue repair and inflammatory response as part of body composition research, our BPC-157/TB-500 blend pairs well with GH-releasing compounds, providing supportive environments for optimized outcomes.
Related Research: Metabolism Boost and Aging
One of the most exciting research avenues for GH-releasing peptides like tesamorelin is their potential to counteract age-related metabolic decline. As the body ages, endogenous GH and IGF-1 levels plummet, leading to increased visceral fat, loss of muscle mass, and a slowdown in metabolism. Tesamorelin offers a route to restoring youthful hormonal profiles and supporting healthy cellular metabolism.
Enhancing metabolism with tesamorelin research studies may include:
– Improved mitochondrial biogenesis (energy powerhouses)
– Heightened fat oxidation at rest and during activity
– Enhanced nutrient partitioning (more nutrients go to muscle, less to fat storage)
Aging researchers may find synergy in stacking tesamorelin with other metabolic-supporting peptides like MOTS-c, which targets mitochondrial function and energy regulation.
GH-releasing tesamorelin is lauded for its ability to safely and consistently increase IGF-1 levels within normal physiological ranges, even in older or metabolically impaired subjects. IGF-1 is a key mediator of GH’s anabolic and lipolytic effects, facilitating:
Balanced IGF-1 elevations are essential because excessively high levels can carry risks, whereas normalizing IGF-1 through physiologic pathways (as with tesamorelin) supports safe research into anti-aging, obesity, and muscle preservation.
For more on supporting IGF-1 pathways in research, review our premium Sermorelin, another trusted GHRH analog available at OathPeptides.com.
Tesamorelin and Non-Alcoholic Fatty Liver Disease (NAFLD)
One of the most compelling recent research developments involves tesamorelin’s effects on hepatic steatosis. A randomized, double-blind, multicenter trial published in The Lancet HIV demonstrated that tesamorelin reduced hepatic fat fraction by 37% relative to baseline in HIV-infected individuals with NAFLD. Remarkably, 35% of tesamorelin recipients achieved normal liver fat levels (below 5%) versus only 4% in the placebo group. Tesamorelin recipients were also significantly less likely to experience progression of liver fibrosis [7].
Safety Profile and Compliance
All products mentioned, including GH-releasing tesamorelin and related peptides, are strictly for research purposes and not for human or animal use. Clinical studies indicate that tesamorelin is generally well-tolerated, with the most common adverse events being injection-site reactions, arthralgia, myalgia, and paresthesia. Importantly, tesamorelin does not appear to significantly alter glucose metabolism or CD4+ T-cell counts, supporting its favorable safety profile for continued research [2, 6].
FAQ – Tesamorelin and GH-Releasing Research
1. What makes tesamorelin different from direct GH administration?
Tesamorelin stimulates the body’s own GH production in natural pulses, reducing the risk of side effects associated with exogenous GH, such as edema, glucose intolerance, and desensitization.
2. Can tesamorelin be combined with other peptides in research?
Yes. Many researchers explore combination protocols with other metabolism- or repair-focused peptides, such as CJC-1295, Ipamorelin, or BPC-157/TB-500 for multi-targeted effects.
3. How quickly does tesamorelin impact visceral fat in research models?
Significant changes in visceral fat and body composition have been observed within 26 weeks in multiple randomized controlled trials, with measurable IGF-1 elevations occurring within the first two weeks of treatment [1, 3].
4. Is tesamorelin only used for fat loss research?
No. Ongoing research examines tesamorelin for age-related hormone decline, metabolic syndrome, cardiovascular health, hepatic steatosis, and NAFLD, among others.
5. Are results from tesamorelin research sustainable over time?
Longer-term studies and meta-analyses suggest that tesamorelin maintains improved body composition and metabolic health markers over sustained periods. A post hoc analysis of a phase III trial also confirmed that tesamorelin is equally effective regardless of the presence of dorsocervical fat accumulation [8].
IMPORTANT: All peptide products are strictly for laboratory research purposes only. Not for human consumption, therapeutic use, or animal treatment.
Conclusion: Why Choose GH-Releasing Tesamorelin for Your Research?
GH-releasing tesamorelin stands at the frontier of metabolism and obesity research, offering unparalleled specificity for visceral fat reduction, fat metabolism, and IGF-1 modulation. At Oath Research, we strive to support the scientific community with rigorously tested peptides, including tesamorelin, CJC-1295/Ipamorelin, and hGH Fragment 176-191, all designed strictly for investigative use. If your research demands innovation in body composition or metabolic health, explore our premium tesamorelin at OathPeptides.com and discover what targeted GH-releasing peptides can deliver.
Ready to advance your investigations? Explore tesamorelin and related peptides, and contact Oath Research for custom support on your next project.
—
References
1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
2. Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. https://pubmed.ncbi.nlm.nih.gov/41545261/
3. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
4. Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(14):e140134. https://pubmed.ncbi.nlm.nih.gov/32701508/
5. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
6. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(13):1897-1902. https://pubmed.ncbi.nlm.nih.gov/38905488/
7. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. https://pubmed.ncbi.nlm.nih.gov/31611038/
8. Rahman F, McLaughlin T, Mesquita P, et al. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e45. https://pubmed.ncbi.nlm.nih.gov/36845310/
For research professionals only. All Oath Research products are strictly for research purposes and not for human or animal use.
For scientific excellence in every batch, trust your GH-releasing tesamorelin and peptide needs to OathPeptides.com.
Discover how KPV peptide, a powerful anti-inflammatory peptide, is revolutionizing research with its impressive ability to calm inflammation and support innovative scientific breakthroughs. Dive in to explore the science behind this standout peptide and why it’s capturing the attention of researchers everywhere.
Curious about how GHRP-6 Acetate Peptide can enhance recovery and boost performance? By harnessing its unique action on ghrelin, appetite, and powerful gh-pulse signaling, this remarkable gh-secretagogue is capturing the attention of researchers and athletes alike.
Discover how oxytocin, often called the social peptide, weaves a powerful chemistry of trust that shapes our bonds, empathy, and emotional wellness. Join us as we explore the fascinating science behind oxytocin and its remarkable impact on social connections.
GH-Releasing Tesamorelin: Stunning Visceral Fat & Metabolism Boost
GH-releasing tesamorelin has rapidly shaken up the landscape for metabolic research, opening new doors for understanding how to control visceral fat, stimulate lipolysis, and revolutionize body composition management. As a potent synthetic growth hormone-releasing hormone (GHRH) analog, tesamorelin has captured the attention of scientists and clinicians alike, thanks to its targeted effects on metabolism, visceral-fat reduction, and IGF-1 secretion.
Important: Tesamorelin and all peptides discussed in this article are strictly for laboratory research purposes only and are not intended for human consumption, therapeutic use, or animal treatment.
Tesamorelin represents a strategically designed peptide structure that enhances endogenous secretion of growth hormone (GH), setting off a remarkable cascade that influences not only body composition but also cardiovascular health markers. At Oath Research (OathPeptides.com), we are at the forefront of providing research-quality tesamorelin for investigative purposes. Let’s take an in-depth look at the science and promise behind this outstanding GH-releasing compound.
GH-Releasing Tesamorelin: How It Targets Visceral Fat and Drives Lipolysis
The focus on GH-releasing peptides like tesamorelin is due largely to their unique ability to modulate the body’s endocrine system without the side effects associated with exogenous growth hormone administration. Tesamorelin acts as a selective GHRH analog, stimulating the pituitary to release GH in pulsatile bursts—closely mimicking natural secretion patterns. This matters because accurate GH pulsatility is crucial for optimal metabolic signaling, particularly with respect to lipolysis and visceral fat decomposition.
Research reveals that tesamorelin’s most dramatic effect lies in its capacity to reduce visceral fat—the deep, metabolically active fat surrounding internal organs. In a landmark randomized trial published in the New England Journal of Medicine, tesamorelin decreased visceral adipose tissue by 15.2% compared to a 5.0% increase in the placebo group over 26 weeks, while also significantly reducing triglyceride levels [1]. Unlike subcutaneous fat, visceral adiposity increases inflammation, disrupts insulin sensitivity, and raises cardiovascular risk. Tesamorelin’s action triggers a surge in GH, which in turn elevates IGF-1 levels. The downstream signaling through IGF-1 lends further support to fat breakdown (lipolysis), muscle preservation, and an overall improvement in body composition.
A pivotal aspect here is tesamorelin’s selectivity: while it potently reduces visceral fat, it generally spares subcutaneous fat and does not lead to significant muscle wasting, making it a valuable tool for research into metabolic syndrome, HIV-associated lipodystrophy, and general obesity. A 2026 meta-analysis of five randomized controlled trials confirmed that tesamorelin produces significant reductions in visceral adipose tissue and trunk fat while increasing lean body mass, without significantly affecting subcutaneous fat or BMI [2].
Mechanisms: Tesamorelin, IGF-1, and Metabolism Optimization
How exactly does GH-releasing tesamorelin support a better metabolism? The peptide’s primary mechanism is by binding to and activating GHRH receptors on the pituitary gland, rapidly elevating GH release. GH, in turn, acts on multiple tissues:
– Adipose Tissue: Stimulates direct lipolysis by activating hormone-sensitive lipase, which breaks down stored triglycerides into free fatty acids. A study by Stanley et al. demonstrated that once-daily tesamorelin augments both basal and pulsatile GH secretion while preserving peripheral insulin-stimulated glucose uptake [3].
– Liver: Boosts IGF-1 synthesis, a critical growth factor that further amplifies fat breakdown and promotes muscle protein synthesis.
– Muscle: Drives anabolic processes, increasing lean mass while metabolizing adipose deposits.
This multi-targeted cascade is why tesamorelin and similar GH-releasing compounds have become cornerstones for metabolic and obesity research. Recent clinical data also points toward improved glucose metabolism, reduced inflammatory markers, and increased mitochondrial efficiency in energy utilization. Notably, transcriptomic analysis of liver biopsies from tesamorelin-treated subjects revealed increased expression of genes involved in oxidative phosphorylation and decreased expression of inflammatory pathway genes [4].
All tesamorelin research referenced herein is conducted under controlled laboratory conditions. These peptides are sold for research purposes only and are not for human or animal use.
Interested researchers can compare the effects of GH-releasing tesamorelin with our premium CJC-1295/Ipamorelin blend, another potent GHRH/GHRP synergistic peptide available at OathPeptides.com.
Body Composition: Real-World Improvements from GH-Releasing Peptides
Body composition—the ratio of fat to lean mass—matters immensely for overall health, longevity, and athletic performance. Studies consistently show that tesamorelin significantly decreases both total and visceral fat, improves waist circumference, and stabilizes lean muscle tissue. A randomized clinical trial published in JAMA found that tesamorelin reduced visceral adipose tissue by approximately 42 cm² and hepatic lipid content by 2.9% over six months compared to placebo [5].
What sets tesamorelin apart is its ability to lower deep abdominal fat (visceral fat), the most dangerous form associated with metabolic syndrome, diabetes, and cardiovascular risk. By ramping up endogenous GH and raising IGF-1, tesamorelin increases lipolysis without the water retention, insulin resistance, or desensitization sometimes seen with exogenous hGH.
For researchers seeking broader insights into body composition optimization, the hGH Fragment 176-191 also offers unique fat-burning properties and is available for research at OathPeptides.com.
Beyond Visceral Fat: Effects on Cardiometabolic Health
The influence of GH-releasing tesamorelin extends well beyond fat tissue. By consistently reducing visceral fat, tesamorelin research shows:
– Decreased triglyceride and cholesterol levels
– Lowered C-reactive protein (CRP), a key inflammation biomarker
– Improved liver fat content (hepatic steatosis) and liver function
These secondary benefits underscore the profound impact of visceral adiposity on chronic disease risk. Researchers are finding that addressing visceral fat with tesamorelin may confer ripple effects on the entire metabolic network, possibly improving insulin sensitivity and cardiovascular health over time. Notably, a 2024 study demonstrated that tesamorelin remains effective in reducing visceral and hepatic fat even in patients on integrase inhibitor-based antiretroviral regimens, which are themselves associated with weight gain [6].
Tesamorelin and Lipolysis: Unmatched Specificity
“Lipolysis” is the technical term for fat breakdown – a process critical for researchers exploring obesity, fatty liver disease, and aging-related weight gain. Tesamorelin’s distinct advantage lies in targeted, visceral fat-specific lipolysis, not simply a broad reduction in all types of adipose tissue.
By leveraging the natural pulsatility of endogenous growth hormone, GH-releasing tesamorelin avoids excessive systemic effects, focusing its fat-reducing power on those stubborn internal stores that most impact health.
For investigators interested in tissue repair and inflammatory response as part of body composition research, our BPC-157/TB-500 blend pairs well with GH-releasing compounds, providing supportive environments for optimized outcomes.
Related Research: Metabolism Boost and Aging
One of the most exciting research avenues for GH-releasing peptides like tesamorelin is their potential to counteract age-related metabolic decline. As the body ages, endogenous GH and IGF-1 levels plummet, leading to increased visceral fat, loss of muscle mass, and a slowdown in metabolism. Tesamorelin offers a route to restoring youthful hormonal profiles and supporting healthy cellular metabolism.
Enhancing metabolism with tesamorelin research studies may include:
– Improved mitochondrial biogenesis (energy powerhouses)
– Heightened fat oxidation at rest and during activity
– Enhanced nutrient partitioning (more nutrients go to muscle, less to fat storage)
Aging researchers may find synergy in stacking tesamorelin with other metabolic-supporting peptides like MOTS-c, which targets mitochondrial function and energy regulation.
IGF-1: Linking Growth, Fat Loss, and Anabolism
GH-releasing tesamorelin is lauded for its ability to safely and consistently increase IGF-1 levels within normal physiological ranges, even in older or metabolically impaired subjects. IGF-1 is a key mediator of GH’s anabolic and lipolytic effects, facilitating:
– Increased lean muscle mass synthesis
– Enhanced fat breakdown
– Accelerated tissue repair processes
Balanced IGF-1 elevations are essential because excessively high levels can carry risks, whereas normalizing IGF-1 through physiologic pathways (as with tesamorelin) supports safe research into anti-aging, obesity, and muscle preservation.
For more on supporting IGF-1 pathways in research, review our premium Sermorelin, another trusted GHRH analog available at OathPeptides.com.
Tesamorelin and Non-Alcoholic Fatty Liver Disease (NAFLD)
One of the most compelling recent research developments involves tesamorelin’s effects on hepatic steatosis. A randomized, double-blind, multicenter trial published in The Lancet HIV demonstrated that tesamorelin reduced hepatic fat fraction by 37% relative to baseline in HIV-infected individuals with NAFLD. Remarkably, 35% of tesamorelin recipients achieved normal liver fat levels (below 5%) versus only 4% in the placebo group. Tesamorelin recipients were also significantly less likely to experience progression of liver fibrosis [7].
Safety Profile and Compliance
All products mentioned, including GH-releasing tesamorelin and related peptides, are strictly for research purposes and not for human or animal use. Clinical studies indicate that tesamorelin is generally well-tolerated, with the most common adverse events being injection-site reactions, arthralgia, myalgia, and paresthesia. Importantly, tesamorelin does not appear to significantly alter glucose metabolism or CD4+ T-cell counts, supporting its favorable safety profile for continued research [2, 6].
FAQ – Tesamorelin and GH-Releasing Research
1. What makes tesamorelin different from direct GH administration?
Tesamorelin stimulates the body’s own GH production in natural pulses, reducing the risk of side effects associated with exogenous GH, such as edema, glucose intolerance, and desensitization.
2. Can tesamorelin be combined with other peptides in research?
Yes. Many researchers explore combination protocols with other metabolism- or repair-focused peptides, such as CJC-1295, Ipamorelin, or BPC-157/TB-500 for multi-targeted effects.
3. How quickly does tesamorelin impact visceral fat in research models?
Significant changes in visceral fat and body composition have been observed within 26 weeks in multiple randomized controlled trials, with measurable IGF-1 elevations occurring within the first two weeks of treatment [1, 3].
4. Is tesamorelin only used for fat loss research?
No. Ongoing research examines tesamorelin for age-related hormone decline, metabolic syndrome, cardiovascular health, hepatic steatosis, and NAFLD, among others.
5. Are results from tesamorelin research sustainable over time?
Longer-term studies and meta-analyses suggest that tesamorelin maintains improved body composition and metabolic health markers over sustained periods. A post hoc analysis of a phase III trial also confirmed that tesamorelin is equally effective regardless of the presence of dorsocervical fat accumulation [8].
IMPORTANT: All peptide products are strictly for laboratory research purposes only. Not for human consumption, therapeutic use, or animal treatment.
Conclusion: Why Choose GH-Releasing Tesamorelin for Your Research?
GH-releasing tesamorelin stands at the frontier of metabolism and obesity research, offering unparalleled specificity for visceral fat reduction, fat metabolism, and IGF-1 modulation. At Oath Research, we strive to support the scientific community with rigorously tested peptides, including tesamorelin, CJC-1295/Ipamorelin, and hGH Fragment 176-191, all designed strictly for investigative use. If your research demands innovation in body composition or metabolic health, explore our premium tesamorelin at OathPeptides.com and discover what targeted GH-releasing peptides can deliver.
Ready to advance your investigations? Explore tesamorelin and related peptides, and contact Oath Research for custom support on your next project.
—
References
1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
2. Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. https://pubmed.ncbi.nlm.nih.gov/41545261/
3. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
4. Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(14):e140134. https://pubmed.ncbi.nlm.nih.gov/32701508/
5. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
6. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(13):1897-1902. https://pubmed.ncbi.nlm.nih.gov/38905488/
7. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. https://pubmed.ncbi.nlm.nih.gov/31611038/
8. Rahman F, McLaughlin T, Mesquita P, et al. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e45. https://pubmed.ncbi.nlm.nih.gov/36845310/
For research professionals only. All Oath Research products are strictly for research purposes and not for human or animal use.
For scientific excellence in every batch, trust your GH-releasing tesamorelin and peptide needs to OathPeptides.com.
Related Posts
KPV Peptide: Stunning Anti‑Inflammatory Peptide for Best Results
Discover how KPV peptide, a powerful anti-inflammatory peptide, is revolutionizing research with its impressive ability to calm inflammation and support innovative scientific breakthroughs. Dive in to explore the science behind this standout peptide and why it’s capturing the attention of researchers everywhere.
GHRP-6 Acetate Peptide: Stunning Recovery & Performance Boost
Curious about how GHRP-6 Acetate Peptide can enhance recovery and boost performance? By harnessing its unique action on ghrelin, appetite, and powerful gh-pulse signaling, this remarkable gh-secretagogue is capturing the attention of researchers and athletes alike.
Oxytocin Social Peptide: The Ultimate Chemistry of Trust
Discover how oxytocin, often called the social peptide, weaves a powerful chemistry of trust that shapes our bonds, empathy, and emotional wellness. Join us as we explore the fascinating science behind oxytocin and its remarkable impact on social connections.